The Global NASH Council Newsletter Edition 7 June 2024

Dear Colleagues, We hope this message finds you well. We're excited to share the latest GNC updates with you through our newsletter. In this edition, we have included updates on: Our Global Liver Registry programs Recent GNC meetings Current project activities Presentations to scientific societies We greatly appreciate your contributions and active participation! We look forward to our continued collaboration. Best regards, The Global NASH Council

Annual Meeting of the Global NASH Council (GNC) and Global Liver Council (GLC) June 8, 2024, ILC 2024, Milan Italy

This year, we had a highy successful GNC/GLC meeting during EASL 2024 in Milan, Italy which was attended by 77 members (65 in person and 12 via zoom). These members represented leaders in the field of liver disease, endocrinology, nutrition and patient representatives from most regions of the world. During the meeting, an overview of the growth and activities of the Councils and a summary of the large scale projects undertaken by the Council members were provided. These projects included the results of the Global NAFLD Stigma survey from patients and providers, the impact of the nomencalture change on evidence (mortality outcomes, NITs and PROs), initial results of the large mega-analysis of 16,000 liver biopsies from MASLD patients, Cost of Inaction about MASLD (Economic burden of MASLD) in 6 countries (US, Germany, Japan, Spain, Saudi Arabia and Brazil), NIT Threshold Global Survey and Enhancing the Implementation of MASLD/MASH Guidelines Across the Globe (EIMG). Furthermore, co-chairs of each of the 10 committees of GNC/GLC provided their reports and future plans. Academic productivity and future regional meetings were discussed.

Scientific Presentations at the International Liver Congress 2024, Milan, Italy

This week members of the Global NASH Council and Global Liver Council will be sharing 11 research presentations at the International Liver Congress 2024 in Milan, Italy. Also, members pf GNC are actively participating as faculty in different scientific programs of ILC 2024. Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States, Zobair M Younossi, Jeffrey V. Lazarus, Alina M. Allen, Kenneth Cusi, Frank Tacke, Michael Roden, Jorn M. Schattenberg, Henry E. Mark, Linda Henry, Fatema Nader, James Paik. Prevalence and mortality of the spectrum of steatotic liver disease (SLD) in the US populations, Zobair M Younossi, Linda Henry, Pegah Golabi, Leyla de Avila, Ryuki Hashida, James Minhui Paik. Association of Quantitative Hepatic Collagen with Non-Invasive Tests (NITs) for Fibrosis in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), Zobair M Younossi, James M. Estep, Sean C. Felix, Brian P. Lam, Daisong Tan, Aaron B. Koenig, Fanny Monge, Andrei Racila, Zachary Goodman, Maria Stepanova. Association of non-invasive tests (NITs) with genetic polymorphism in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), Zobair M Younossi, James M. Estep, Zohal Zekrya, Sean C. Felix, Brian P. Lam, Zaid Younossi, Andrei Racila, Maria Stepanova. Food swamps and easy access to unhealthy food increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) mortality in the United States (U.S.), Annette Paik, Linda Henry, Leyla de Avila, Saleh Alqahtani, Fatema Nader, James Minhui Paik, Zobair M Younossi. Associations of food insecurity and healthcare access with the prevalence and mortality of metabolic dysfunction-associated steatotic liver disease (MASLD): a global study of the United Nation and the global burden of disease data, Zobair M Younossi, Shira Zelber-Sagi, Carina Kugelmas, Jeffrey V. Lazarus, Annette Paik, Leyla de Avila, Lynn Gerber, James Minhui Paik Health-Related Quality of Life (HRQL) assessments in a 52-Week, double-blind, randomized, placebo-controlled phase 3 study of Resmetirom (MGL-3196) in patients with nonalcoholic steatohepatitis (NASH) and fibrosis (MAESTRO-NASH), Zobair M Younossi, Maria Stepanova, Andrei Racila, Linda Henry, Keith Miller, Dominic Labriola, Rebecca A Taub, Fatema Nader. Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Zobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, Vasily Isakov, Marlen Castellanos-Fernandez, Vincent Wai-Sun Wong, Yuichiro Eguchi, Manuel Romero-Gomez, Nahum Mendez-Sanchez, Ajay Duseja, Caglayan Keklikkiran, Jacob George, Elisabetta Bugianesi, Ashwani K. Singal, Saeed S Hamid, Khalid Aida Alswat, Wah Kheong Chan, Jian-Gao Fan, George A Papandreou, Stuart C. Gordon, Mohamed El Kassas, Stuart Roberts, Brian P. Lam, Andrei Racila, Linda Henry, Saleh Alqahtani, Maria Stepanova. In Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Clinically Significant Pruritus is Associated with High Serum Bile Acid (BA) Level and Advanced Fibrosis (AF), Zobair M Younossi, James M. Estep, Sean C. Felix, BP. Lam, Sumanta Mukherjee, Brandon Swift, Linda Casillas, Andrea Ribeiro, Jake Hunnicutt, Megan Mclaughlin, A Racila, Fatema Nader, Maria Stepanova Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH), Zobair M. Younossi, Maria Stepanova, Issah Younossi, Andrei Racila. Assessments of health utilities in patients with metabolic dysfunction-associated steatohepatitis (MASH): cross-walk between CLDQ-NASH, SF-6D, and the EuroQol EQ-5D, Zobair M Younossi, Maria Stepanova, Jesse Fishman, James Dodge, Dominic Labriola, Rebecca A Taub, Fatema Nader.